The purpose of Idorsia is to discover,
develop and bring more, innovative medicines to patients.
To achieve this, we will develop Idorsia into one of Europe’s
leading biopharmaceutical companies, with a strong scientific core.
We have identified five key strategic priorities to ensure
the company’s success over the first 5 years.
We have a diversified and balanced clinical development
pipeline covering multiple therapeutic areas,
including CNS, cardiovascular and immunological
disorders, as well as orphan diseases.
We bring new perspectives to the development
of innovative compounds, challenging accepted
paradigms to answer the questions that matter
to patients. Our key assets have the potential to
transform treatment in the target indications.
From bench to bedside
A long-term strategic perspective is vital
to ensure that our drugs address important
healthcare challenges. A smart company must
adopt creative approaches to delivering its
medicines to patients.
To maximize the benefit of our pioneering
therapies for patients, we will consider
strategic partnerships and build our own
commercial infrastructure to provide access
to our drugs in certain therapeutic fields.
Becoming a sustainable company
We are building Idorsia with a long-term focus and ambitious aspirations. We will run the
company in a responsible and sustainable way. Becoming profitable will provide us with financial
independence and secure our future.
Idorsia has the potential to generate significant revenues from product sales once the first of its pipeline candidates has received regulatory approval for commercialization. In the meantime,
Idorsia has generated revenue through a milestone payment from its collaboration with Janssen on the co-development and commercialization of aprocitentan; this collaboration could also generate royalty payments. Furthermore, Idorsia could benefit from revenue-sharing payments relating to
potential sales of ponesimod.
We are providing a supportive and stimulating environment for high-performing teams, recognizing and rewarding their contributions.
Building a bright future
Idorsia is a high-potential biopharmaceutical
company with a balanced portfolio of innovative drugs.
As our assets advance and reach the market,
there is a need to constantly replenish the
pipeline with innovative compounds. This is
where our highly productive drug discovery engine
We are passionate and curious scientists,
determined to help patients function better,
feel better and live longer. Our drug discovery
focuses on creating small molecules that are active
on well-selected molecular targets. Knowledge
built through the development of drugs active
on one target can often benefit projects in
several therapeutic areas.
Our focus on disorders with a high medical need
means that our discoveries create significant
value for patients, payors and society in general.
Utilize state-of-the-art technologies
As we want to remain at the cutting edge of science,
it is vital that we consider innovative approaches
from bench to bedside. We must integrate computational
tools and digital technologies at different stages
of the drug discovery, development and commercialization
process, to maximize our potential and bring
breakthrough medicines to patients.
Idorsia will look for creative ways to harness
advances in technology to focus on novel targets
and use new drug development methods. All
functions of Pharmaceutical Development are
streamlined to ensure the delivery of technically
tailored and high-quality medicines. As the
company establishes its commercial infrastructure,
we will look for opportunities to use technology
to benefit as many patients as possible.
When it comes to our colleagues’ daily life at
Idorsia, we also employ pragmatic solutions to
minimize the need for bureaucracy. Continuous
learning and work-life balance are important
engagement drivers to ensure that everyone
thrives at Idorsia.